Kenneth James Smith1, Mitchel Berger2, Susan Chang3, Rachel Smith, Tracy Richmond McKnight
1Radiology & Biomedical Imaging, University of California San Francisco , San Francisco, CA, United States; 2Neurosurgery, University of California San Francisco; 3Neuro Oncology, University of California San Francisco
Loss of 1p and 19q heterozygosity has been identified as a primary prognostic factor in glial tumors, regardless of treatment. Patients have significantly higher progression free survival as well as an increased response to chemotherapy when they exhibit a co-deletion in the 1p and 19q chromosomal arms. Our Goal, using High Resolution Magic Angle Spinning (HRMAS) MRS, was to investigate whether or not 1p19q influenced tumor metabolism. We found significantly higher concentration of creatine as well as glutamine in tumors that did not exhibit a loss of 1p and 19q heterozygosity.